E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prophylactic respiratory syncytial virus (RSV) vaccine. |
|
E.1.1.1 | Medical condition in easily understood language |
Preventive vaccine against RSV. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess a trend for the prophylactic efficacy of a single dose of 1x10e11 vp of Ad26.RSV.preF administered intramuscularly to adults aged 18-50 years in the RSV challenge model in terms of reduction of nasal wash viral load as measured by the area under the curve (AUC) over time by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) compared to placebo. |
|
E.2.2 | Secondary objectives of the trial |
-To assess a trend for prophylactic efficacy of a single dose of Ad26.RSV.preF in the RSV challenge model in terms of reduction of nasal wash viral load as measured by the peak viral load of the RT-PCR compared to placebo. - To assess the effect of a single dose of 1x10e11 vp of Ad26.RSV.preF on viral load, as measured by RT-PCR and quantitative culture of RSV, and clinical symptoms on Day 6 and Day 7 post-challenge compared to placebo. -To assess a trend for prophylactic efficacy of a single dose of 1x10e11 vp of Ad26.RSV.preF in the RSV challenge model in terms of prevention of symptomatic RSV infection defined as two quantifiable RT-PCR measurements and one or more positive clinical symptoms of any grade from two different categories in the symptom scoring system (Upper Respiratory, Lower Respiratory, Systemic), or one Grade 2 symptom from any category compared to placebo.
Full list of secondary objectives is available in section 2 of the protocol.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Subject is a man or woman, ≥18 to ≤50 years old on the day of ICF signature. 2. Subjects must be in good health, without significant medical illness, on the basis of a medical evaluation that reveals the absence of any clinically relevant abnormality and includes a physical examination, and the results of clinical laboratory tests performed within 56 days of vaccination. If there are abnormalities, the subject may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the subject’s source documents and initialed by the investigator. 3. Subjects must have a non-clinically significant 12-lead ECG within 56 days of vaccination including: a) normal sinus rhythm (heart rate between 50 and 100 beats per minute [bpm], extremes included) b) QT interval corrected for heart rate according to Fridericia (QTcF) interval ≤450 ms c) QT interval corrected for heart rate according to Bazett (QTcB) interval ≤450 ms d) QRS interval <120 ms e) PR interval ≤210 ms. Note: Retesting of abnormal ECG values that may lead to exclusion will be allowed once without prior approval from the sponsor. Repeate ECG due to equipment failure will not count as a retest. Subjects with a normal value at retest may be included. 4. Subjects must be sero-suitable for RSV within 90 days of vaccination (low immunity to the RSV-A Memphis 37b virus using a virus neutralization assay). 5. Subject must be healthy on the basis of clinical laboratory tests performed within 56 days of vaccinaiton. If the results of the laboratory screening tests are outside the local laboratory normal reference ranges and additionally within the limits of toxicity Grade 1 according to the US Food and Drug Administration (FDA) toxicity tables (ie, for tests in the FDA table ), the subject may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant and appropriate and reasonable for the population under study. This determination must be recorded in the subject’s source documents and initialed by the investigator. Note: If laboratory screening tests are out of local laboratory normal ranges and deemed clinically significant, repeat of screening tests is permitted once using an unscheduled visit during the screening period to assess eligibility.
Further criteria are defined in section 4.1 of the protocol.
|
|
E.4 | Principal exclusion criteria |
1. Subject has a history of an underlying clinically significant acute or chronic medical condition or physical examination findings for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise the wellbeing) or that could prevent, limit, or confound the protocol-specified assessments. 2. Subject has chronic active hepatitis B or hepatitis C infection, documented by hepatitis B surface antigen and hepatitis C antibody, respectively or current human immunodeficiency virus type 1 (HIV-1) or HIV-2 infection. 3. Subject has previously participated in, or is currently participating in an RSV vaccine study, has previously received treatment with immunoglobulin or blood products in the 4 months before the planned administration of study vaccine or has any plans to receive such treatment during the study. 4. Subject has a history of chronic urticaria (recurrent hives), eczema and/or atopic dermatitis or has a history of acute polyneuropathy (eg, Guillain-Barré syndrome). 5. Subject has abnormal function of the immune system resulting from: - clinical conditions (e.g. autoimmune disease or immunodeficiency) - chronic (longer than 10 days) or recurrent use of systemic corticosteroids during the study and within 6 months before administration of study vaccine (Note: occular, topical or inhaled steroids are allowed) - Administration of antineoplastic and immunomodulating agents or radiotherapy during the study and within 6 months before administration of study vaccine.
Further criteria are defined in section 4.2 of the protocol. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the VL-AUC (area under curve for viral load) of RSV-A Memphis 37b as determined by quantitative RT-PCR assay of nasal wash samples. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Nasal wash samples are taken every 12 (±1) hours beginning two days after inoculation of the challenge virus until discharge from the challenge Unit. |
|
E.5.2 | Secondary end point(s) |
1. Peak viral load of RSV-A Memphis 37b, defined as the maximum viral load as determined by quantitative RT-PCR assay of nasal wash samples, observed over the entire time period.
2. Occurrence of symptomatic RSV infection defined as two quantifiable RT-PCR measurements at different time points plus symptoms of any grade from two different categories from the subject symptom card (SSC) or two quantifiable RT-PCR measurements plus any Grade 2 symptom from any category. The three SSC categories are: - Upper Respiratory symptoms: runny nose, stuffy nose, sneezing, sore throat, earache - Lower Respiratory symptoms: cough, shortness of breath, chess tightness, wheeze - Systemic symptoms: malaise, headache, muscle and/or joint ache, chilliness/ feverishness
3. Occurrence of RSV infection defined as two quantifiable RT-PCR measurements plus any clinical symptom of any severity.
4. Total weight of mucus produced and tissue count.
5. Safety and tolerability - Unsolicited adverse events (AEs) from informed consent form (ICF) signature until 28 days after vaccination, and from the entry into the Unit until 28 days after challenge. - Safety data including, but not limited to, physical examinations, vital signs, 12-lead electrocardiograms (ECGs) and clinical laboratory results (including biochemistry, hematology, and urinalysis). - Serious adverse events (SAEs) throughout the study (from signing the ICF to the end of the study, 6 months after vaccination). - Solicited local and systemic AEs for 7 days after vaccination. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Nasal wash samples are taken every 12 (±1) hours beginning two days after inoculation of the challenge virus until discharge from the challenge Unit.
2. 3 and 4 -samples collected at multiple timepoints until discharge from the challenge unit
5. - unsolicited AEs from ICF signature until 28 days after vaccination and from entry to the Unit (Day -2 or -1) until 28 days after challenge - safety data throughout the study - SAEs throughout the study - solicited local and systemic AEs for 7 days after vaccination
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tolerability, Immunogenicity |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |